Absci (ABSI) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.74 billion vs $1.58 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | GENB |
|---|---|---|
| Share price | $9.22 | $13.57 |
| Market cap | $1.58B | $1.74B |
| 1-day change | -10.22% | -1.67% |
| YTD return | +164.18% | — |
| 1-year return | +146.52% | — |
| 5-year return | -13.26% | — |
| EPS (TTM) | $-0.79 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $22.67 |
| 52-week low | $2.24 | $11.00 |
| Distance from 52-week high | -23.52% | -40.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +56.18% | +98.97% |
| Average volume | 3.45M | 1.04M |
| Shares outstanding | 171.61M | 128.35M |
| Employees | 140 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
ABSI vs GENB FAQ
Which is bigger, Absci or Generate Biomedicines?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.74B compared with $1.58B for Absci (ABSI).
Are Absci and Generate Biomedicines in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Generate Biomedicines.